Margaret K. Hahn, Ph.D. - Publications

2013 University of Toronto, Toronto, ON, Canada 
Pharmacology, Mental Health, Epidemiology

32 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Costa-Dookhan KA, Rajji TK, Tran VN, Bowden S, Mueller DJ, Remington GJ, Agarwal SM, Hahn MK. Associations between plasma clozapine/N-desmethylclozapine ratio, insulin resistance and cognitive performance in patients with co-morbid obesity and ultra-treatment resistant schizophrenia. Scientific Reports. 11: 2004. PMID 33479273 DOI: 10.1038/s41598-021-81493-0  0.52
2021 Kowalchuk C, Castellani L, Kanagsundaram P, McIntyre WB, Asgariroozbehani R, Giacca A, Hahn MK. Olanzapine-induced insulin resistance may occur via attenuation of central K channel-activation. Schizophrenia Research. 228: 112-117. PMID 33434724 DOI: 10.1016/j.schres.2020.12.005  0.52
2020 Melamed OC, Hahn MK, Agarwal SM, Taylor VH, Mulsant BH, Selby P. Physical health among people with serious mental illness in the face of COVID-19: Concerns and mitigation strategies. General Hospital Psychiatry. 66: 30-33. PMID 32645586 DOI: 10.1016/j.genhosppsych.2020.06.013  0.32
2020 Shah P, Plitman E, Iwata Y, Kim J, Nakajima S, Chan N, Brown EE, Caravaggio F, Torres E, Hahn M, Chakravarty MM, Remington G, Gerretsen P, Graff-Guerrero A. Glutamatergic neurometabolites and cortical thickness in treatment-resistant schizophrenia: Implications for glutamate-mediated excitotoxicity. Journal of Psychiatric Research. 124: 151-158. PMID 32169688 DOI: 10.1016/j.jpsychires.2020.02.032  0.88
2019 Costa-Dookhan KA, Agarwal SM, Chintoh A, Tran VN, Stogios N, Ebdrup BH, Sockalingam S, Rajji TK, Remington GJ, Siskind D, Hahn MK. The clozapine to norclozapine ratio: A narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy. Expert Opinion On Drug Safety. PMID 31770500 DOI: 10.1080/14740338.2020.1698545  0.52
2019 Shah P, Iwata Y, Brown EE, Kim J, Sanches M, Takeuchi H, Nakajima S, Hahn M, Remington G, Gerretsen P, Graff-Guerrero A. Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study. European Archives of Psychiatry and Clinical Neuroscience. PMID 31428862 DOI: 10.1007/s00406-019-01053-6  0.88
2019 Kowalchuk C, Kanagasundaram P, McIntyre WB, Belsham DD, Hahn MK. Direct effects of antipsychotic drugs on insulin, energy sensing and inflammatory pathways in hypothalamic mouse neurons. Psychoneuroendocrinology. 109: 104400. PMID 31404896 DOI: 10.1016/j.psyneuen.2019.104400  0.32
2019 Gorbovskaya I, Kanji S, Liu JCW, MacKenzie NE, Agarwal SM, Marshe VS, Sriretnakumar V, Verdu EF, Bercik P, De Palma G, Hahn MK, Müller DJ. Investigation of the Gut Microbiome in Patients with Schizophrenia and Clozapine-Induced Weight Gain: Protocol and Clinical Characteristics of First Patient Cohorts. Neuropsychobiology. 1-8. PMID 30928978 DOI: 10.1159/000494696  0.32
2019 Kowalchuk C, Kanagasundaram P, Belsham DD, Hahn MK. Antipsychotics differentially regulate insulin, energy sensing, and inflammation pathways in hypothalamic rat neurons. Psychoneuroendocrinology. 104: 42-48. PMID 30802709 DOI: 10.1016/j.psyneuen.2019.01.029  0.32
2018 MacKenzie NE, Kowalchuk C, Agarwal SM, Costa-Dookhan KA, Caravaggio F, Gerretsen P, Chintoh A, Remington GJ, Taylor VH, Müeller DJ, Graff-Guerrero A, Hahn MK. Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia. Frontiers in Psychiatry. 9: 622. PMID 30568606 DOI: 10.3389/fpsyt.2018.00622  0.52
2018 Castellani LN, Wilkin J, Abela A, Benarroch L, Ahasan Z, Teo C, Wilson V, Kowalchuk C, Giacca A, Remington GJ, Hahn MK. Effects of acute olanzapine exposure on central insulin-mediated regulation of whole body fuel selection and feeding. Psychoneuroendocrinology. 98: 127-130. PMID 30142549 DOI: 10.1016/j.psyneuen.2018.07.028  0.6
2018 Kowalchuk C, Castellani L, Chintoh A, Remington G, Giacca A, Hahn M. Antipsychotics and glucose metabolism: how brain and body collide. American Journal of Physiology. Endocrinology and Metabolism. PMID 29969315 DOI: 10.1152/ajpendo.00164.2018  0.88
2017 Raben AT, Marshe VS, Chintoh A, Gorbovskaya I, Müller DJ, Hahn MK. The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment. Frontiers in Neuroscience. 11: 741. PMID 29403343 DOI: 10.3389/fnins.2017.00741  0.52
2017 Kowalchuk C, Teo C, Wilson V, Chintoh A, Lam L, Agarwal SM, Giacca A, Remington GJ, Hahn MK. In male rats, the ability of central insulin to suppress glucose production is impaired by olanzapine, whereas glucose uptake is left intact. Journal of Psychiatry & Neuroscience : Jpn. 42: 424-431. PMID 29083297 DOI: 10.1503/jpn.170092  0.6
2017 Kowalchuk C, Teo C, Wilson V, Chintoh A, Lam L, Agarwal SM, Giacca A, Remington GJ, Hahn MK. In male rats, the ability of central insulin to suppress glucose production is impaired by olanzapine, whereas glucose uptake is left intact. Journal of Psychiatry & Neuroscience : Jpn. 42: 170092. PMID 29035174 DOI: 10.1503/jpn.170092  0.6
2017 Fervaha G, Takeuchi H, Foussias G, Hahn MK, Agid O, Remington G. Achievement motivation in early schizophrenia: Relationship with symptoms, cognition and functional outcome. Early Intervention in Psychiatry. PMID 28230315 DOI: 10.1111/eip.12405  0.88
2016 Remington G, Foussias G, Fervaha G, Agid O, Takeuchi H, Lee J, Hahn M. Treating Negative Symptoms in Schizophrenia: an Update. Current Treatment Options in Psychiatry. 3: 133-150. PMID 27376016 DOI: 10.1007/s40501-016-0075-8  0.88
2016 Benarroch L, Kowalchuk C, Wilson V, Teo C, Guenette M, Chintoh A, Nesarajah Y, Taylor V, Selby P, Fletcher P, Remington GJ, Hahn MK. Atypical antipsychotics and effects on feeding: from mice to men. Psychopharmacology. PMID 27251130 DOI: 10.1007/s00213-016-4324-8  0.6
2016 Remington G, Lee J, Agid O, Takeuchi H, Foussias G, Hahn M, Fervaha G, Burton L, Powell V. Clozapine's Critical Role in Treatment Resistant Schizophrenia: Ensuring Both Safety and Use. Expert Opinion On Drug Safety. PMID 27207070 DOI: 10.1080/14740338.2016.1191468  0.88
2015 Remington GJ, Teo C, Wilson V, Chintoh A, Guenette M, Ahsan Z, Giacca A, Hahn MK. Metformin attenuates olanzapine-induced hepatic, but not peripheral insulin resistance. The Journal of Endocrinology. 227: 71-81. PMID 26330531 DOI: 10.1530/JOE-15-0074  0.6
2015 Caravaggio F, Hahn M, Nakajima S, Gerretsen P, Remington G, Graff-Guerrero A. Reduced insulin-receptor mediated modulation of striatal dopamine release by basal insulin as a possible contributing factor to hyperdopaminergia in schizophrenia Medical Hypotheses. DOI: 10.1016/j.mehy.2015.06.011  0.6
2014 Guenette MD, Chintoh A, Remington G, Hahn M. Atypical antipsychotic-induced metabolic disturbances in the elderly. Drugs & Aging. 31: 159-84. PMID 24477569 DOI: 10.1007/s40266-014-0152-x  0.6
2014 Hahn MK, Chintoh A, Remington G, Teo C, Mann S, Arenovich T, Fletcher P, Lam L, Nobrega J, Guenette M, Cohn T, Giacca A. Effects of intracerebroventricular (ICV) olanzapine on insulin sensitivity and secretion in vivo: an animal model. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 24: 448-58. PMID 24001874 DOI: 10.1016/j.euroneuro.2013.07.011  0.6
2013 Hahn MK, Wolever TM, Arenovich T, Teo C, Giacca A, Powell V, Clarke L, Fletcher P, Cohn T, McIntyre RS, Gomes S, Chintoh A, Remington GJ. Acute effects of single-dose olanzapine on metabolic, endocrine, and inflammatory markers in healthy controls. Journal of Clinical Psychopharmacology. 33: 740-6. PMID 24100786 DOI: 10.1097/JCP.0b013e31829e8333  0.6
2013 Guenette MD, Giacca A, Hahn M, Teo C, Lam L, Chintoh A, Arenovich T, Remington G. Atypical antipsychotics and effects of adrenergic and serotonergic receptor binding on insulin secretion in-vivo: an animal model. Schizophrenia Research. 146: 162-9. PMID 23499243 DOI: 10.1016/j.schres.2013.02.023  0.88
2013 Remington G, Teo C, Mann S, Hahn M, Foussias G, Agid O. Examining levels of antipsychotic adherence to better understand nonadherence. Journal of Clinical Psychopharmacology. 33: 261-3. PMID 23422390 DOI: 10.1097/JCP.0b013e31828568bc  0.88
2013 Remington G, Agid O, Foussias G, Hahn M, Rao N, Sinyor M. Clozapine's role in the treatment of first-episode schizophrenia. The American Journal of Psychiatry. 170: 146-51. PMID 23377634 DOI: 10.1176/appi.ajp.2012.12060778  0.88
2013 Guenette MD, Hahn M, Cohn TA, Teo C, Remington GJ. Atypical antipsychotics and diabetic ketoacidosis: a review. Psychopharmacology. 226: 1-12. PMID 23344556 DOI: 10.1007/s00213-013-2982-3  0.6
2013 Hahn MK, Cohn T, Teo C, Remington G. Topiramate in schizophrenia: a review of effects on psychopathology and metabolic parameters. Clinical Schizophrenia & Related Psychoses. 6: 186-96. PMID 23302448 DOI: 10.3371/CSRP.HACO.01062013  0.6
2013 Tiwari AK, Brandl EJ, Weber C, Likhodi O, Zai CC, Hahn MK, Lieberman JA, Meltzer HY, Kennedy JL, Müller DJ. Association of a functional polymorphism in neuropeptide Y with antipsychotic-induced weight gain in schizophrenia patients. Journal of Clinical Psychopharmacology. 33: 11-7. PMID 23277265 DOI: 10.1097/JCP.0b013e31827d145a  0.6
2010 Hahn MK, Remington G, Bois D, Cohn T. Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects. Journal of Clinical Psychopharmacology. 30: 706-10. PMID 21105286 DOI: 10.1097/JCP.0b013e3181fab67d  0.6
2010 Hahn MK, Cohn T, Remington G. Comment: Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain. The Annals of Pharmacotherapy. 44: 1349-50; author repl. PMID 20587740 DOI: 10.1345/aph.1M550a  0.6
Show low-probability matches.